News for Healthier Living

ASCO: New Antibody-Drug Conjugate Shows Promising Safety and Response Rates for Patients with Rare Blood Cancer

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.

June 2, 2025


June 7 2025

June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025

May 30 2025

May 29 2025

May 28 2025

May 27 2025

May 26 2025

May 25 2025

May 24 2025